Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin

8 september 2026 uppdaterad av: University of Colorado, Denver

The goal of this clinical trial is to learn how atorvastatin in patients with advanced high grade serous cancer of the ovary, fallopian tube, or peritoneum changes the tumor immune environment. The main question it aims to answer is:

  • Does atorvastatin combined with standard of care chemotherapy and surgery changes the number of tumor-promoting macrophages in the tumor microenvironment
  • Researchers will compare standard of care chemotherapy and surgery to see if there is a difference in tumor promoting macrophages.
  • Participants will take atorvastatin (daily pill) alongside their standard treatment.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

40

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Colorado
      • Aurora, Colorado, Förenta staterna, 80045
        • University of Colorado Anschutz

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Be a patient with ovarian cancer aged 18-89
  • Diagnosed via tissue biopsy not ascites
  • For persons of reproductive potential, use of highly effective method(s) of contraception.
  • Patients with primary Stage III/IV high-grade serous ovarian/fallopian tube/primary peritoneal cancer not amenable to upfront cytoreductive surgery.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
  • Absolute Neutrophil Count 1500 cells/mL
  • Platelet count > 100,000 mL.
  • Hemoglobin 9.0 g/dL
  • Serum albumin ³ 2.5 g/dL.
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN).
  • aspartate aminotransferase (AST )and alanine aminotransferase (ALT) ≤ 3.0 x ULN.
  • Serum creatinine ≤ 1.5x ULN

Exclusion Criteria:

  • Inability to comply with study and follow-up procedures.
  • Significant cardiovascular disease, such as New York Heart Association cardiac disease (class II or greater), myocardial infarction within the past 3 months, unstable arrhythmia, or unstable angina.
  • Known clinically significant liver disease defined as AST and ALT > 3.0 x ULN and/or total bilirubin ≥ 1.5 x ULN, or documented history of active viral, alcoholic, or other hepatitis, cirrhosis, and inherited liver disease.
  • Participation in investigational clinical trial within last 30 days.
  • Medical history of untreated HIV infection. Patients with medical history of HIV infection are eligible provided they meet following criteria

    • Are stable on antiretroviral therapy for ≥4 weeks before randomization
    • Agree to adhere to antiretroviral therapy per World Health Organization (WHO) guidelines
    • Have no documented multi-drug resistance that would prevent effective antiretroviral therapy
    • Have a viral load of <400 copies per mL at screening
    • Have CD4+ T cell count at ≥ 350 cells per μL
    • Have no history of acquired immunodeficiency syndrome (AIDS) -defining opportunistic infection ≤ 12 months before randomization.
  • Inability to provide informed consent.
  • Known central nervous system (CNS) malignancy or CNS metastases.
  • Patients with previous malignancy within the past 2 years from cycle 1, day 1, except those with negligible risk of metastasis or death, such as adequately controlled basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the breast.
  • History of stroke or transient ischemic attack (TIA) within 3 months prior to cycle 1 day 1(C1D1).
  • Patients with prognosis for survival less than 6 months.
  • Patients deemed otherwise clinically unfit for clinical trial per Investigator's discretion.
  • Patients with duodenal stent or other gastrointestinal (GI) disorder/defect that would interfere with absorption of oral medication.

    o Includes patients unable to swallow orally administered medication and patients with GI disorders likely to interfere with absorption of the study medication

  • Female patients who maintain fertility potential and refuse to comply to use contraception and be followed for pregnancy by pregnancy testing.
  • Patients who are currently pregnant or lactating.
  • Prior or current statin use that would prohibit randomization into SOC arm.
  • Planned treatment with bevacizumab in the primary treatment setting.
  • Diagnosis based on ascites assessment only and not a tissue biopsy.
  • Patients deemed otherwise clinically unfit for clinical trial per investigators discretion

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Standard of Care
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
Experimentell: Atorvastatin with Standard of Care
Patients in this arm will take atorvastatin daily alongside neoadjuvant chemotherapy with 3-4 cycles of carboplatin/paclitaxel, interval debulking surgery, then 2-3 additional cycles of chemotherapy with carboplatin/paclitaxel
Neoadjuvant chemotherapy with carboplatin and paclitaxel in addition to daily atorvastatin, interval debulking surgery, then 2-3 additional cycles of carboplatin and paclitaxel

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline of CD163+ tumor associated macrophages in post-treatment specimens.
Tidsram: 3 months
The primary efficacy endpoint is the change from baseline to the post-treatment surgical specimen in the mean CD163 H-score among CD68-positive tumor-associated macrophages. CD68 and CD163 expression will be assessed by multispectral immunohistochemistry in paired pre-treatment biopsy and post-treatment surgical samples.
3 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Progression free survival
Tidsram: 5 years
Investigator-assessed progression-free survival will be defined as the time from randomization to the first documented occurrence of objective disease progression or death from any cause, whichever occurs first.
5 years
Overall Survival
Tidsram: 5 years
Overall survival as defined by the time of randomization to time of death from any cause.
5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Nicole Marjon, MD, PhD, CU Anschutz

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 september 2026

Primärt slutförande (Beräknad)

1 augusti 2028

Avslutad studie (Beräknad)

1 augusti 2031

Studieregistreringsdatum

Först inskickad

31 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

8 september 2026

Första postat (Faktisk)

11 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

All data will be de-identified prior to sharing with other researchers

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera